Results 151 to 160 of about 143,738 (310)

Flagellar membrane association via interaction with lipid rafts [PDF]

open access: yes, 2009
The eukaryotic flagellar membrane has a distinct composition from other domains of the plasmalemma. Our work shows that the specialized composition of the trypanosome flagellar membrane reflects increased concentrations of sterols and saturated fatty ...
Cieslak, John A.   +6 more
core   +2 more sources

Natural Products from Mexican Medicinal Plants as Promising Trypanocidal Drugs

open access: yesChemistrySelect, Volume 10, Issue 37, October 6, 2025.
Chagas disease (American Trypanosomiasis) is caused by the protozoan Trypanosoma cruzi. Worldwide it is one of the seventeen neglected tropical diseases. There is a need of new drugs. This review assesses the literature (2012‐2024) of secondary metabolites isolated from Mexican plants active against this parasite.
Karla Daniela Rodríguez‐Hernández   +2 more
wiley   +1 more source

Metabolic changes that allow Plasmodium falciparum artemisinin-resistant parasites to tolerate oxidative stress

open access: yesFrontiers in Parasitology
Artemisinin-based treatments (ACTs) are the first therapy currently used to treat malaria produced by Plasmodium falciparum. However, in recent years, increasing evidence shows that some strains of P.
Alejandro David Bonive-Boscan   +3 more
doaj   +1 more source

Genomic comparison of Trypanosoma conorhini and Trypanosoma rangeli to Trypanosoma cruzi strains of high and low virulence

open access: yesBMC Genomics, 2018
Background Trypanosoma conorhini and Trypanosoma rangeli, like Trypanosoma cruzi, are kinetoplastid protist parasites of mammals displaying divergent hosts, geographic ranges and lifestyles. Largely nonpathogenic T. rangeli and T.
Katie R Bradwell   +12 more
doaj   +1 more source

Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery

open access: yesPLoS Neglected Tropical Diseases, 2015
Background Chagas disease is a neglected tropical disease (NTD) caused by the eukaryotic parasite Trypanosoma cruzi. The current clinical and preclinical pipeline for T. cruzi is extremely sparse and lacks drug target diversity.
S. Ekins   +12 more
semanticscholar   +1 more source

Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras [PDF]

open access: yes, 2009
Between 1999-2002, Médécins Sans Frontières-Spain implemented a project seeking to determine the efficacy and safety of benznidazole in the treatment of recent chronic Chagas disease in a cohort of seropositive children in the Yoro Department, Honduras ...
Bassets, Glòria   +9 more
core   +4 more sources

Biotic Assembly of the Species of Triatomini (Hemiptera: Reduviidae: Triatominae) in the Mexican and South American Transition Zones

open access: yesJournal of Biogeography, Volume 52, Issue 10, October 2025.
ABSTRACT Aim To infer the biogeographic history of the Triatomini by evaluating how their species became part of the biogeographic transition zones of the New World. This group of blood‐feeding insects includes key vectors of Chagas disease. Understanding their dispersal and diversification over geological time may help elucidate the temporal dynamics ...
Andrés Mejía‐Soto   +4 more
wiley   +1 more source

Trypanosoma cruzi and Its Soluble Antigens Induce NET Release by Stimulating Toll-Like Receptors

open access: yesPLoS ONE, 2015
Neutrophils release fibrous traps of DNA, histones, and granule proteins known as neutrophil extracellular traps (NETs), which contribute to microbicidal killing and have been implicated in autoimmunity.
Daniel Sousa-Rocha   +5 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy